Document is current
Any future updates will be listed below
-
Authors
Utsunomiya, Atae https://orcid.org/0000-0002-8843-406X
Tokunaga, Masahito https://orcid.org/0000-0003-1296-9006
Nakano, Nobuaki https://orcid.org/0000-0001-9826-7616
Fujiwara, Hiroshi
Miyamoto, Toshihiro https://orcid.org/0000-0002-6533-1594
Ogata, Masao https://orcid.org/0000-0002-4896-5878
Miyazaki, Yasuhiko
Ishitsuka, Kenji https://orcid.org/0000-0002-7030-497X
Sakaida, Emiko https://orcid.org/0000-0002-7254-1928
Taji, Hirofumi
Wakayama, Toshio
Ichinohe, Tatsuo https://orcid.org/0000-0002-0393-4066
Fukuda, Takahiro
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Kato, Koji
Yoshimitsu, Makoto https://orcid.org/0000-0002-5935-0385
- License Information
-
More Information
Article History
Received: 6 April 2021
Revised: 23 June 2021
Accepted: 5 July 2021
First Online: 23 January 2022
Competing interests
: HF is a member of a department endowed by BrightPath Biotherapeutics. TI has received research funding outside the scope of this work from the following companies: Astellas Pharma; Chugai Pharmaceutical; CSL Behring; Eisai; FUJIFILM Wako Chemicals; Kyowa Kirin; Ono Pharmaceutical; Pfizer; Nippon Shinyaku; MSD; Otsuka Pharmaceutical; Repertoire Genesis; Sumitomo Dainippon Pharma; Taiho Pharmaceutical; Takara Bio; Takeda Pharmaceutical; and Zenyaku Kogyo. The other authors declare that they have no competing interests.
